Cannabinoids in pain and inflammation

Inflammopharmacology

Volumn 12, Issue 2, 2004, Pages 99-114

  Mbvundula, Estery C ^a   Rainsford, K D ^a   Bunning, Rowena A D ^a  

^a SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

Author keywords

Analgesia; Anti nociceptive; Cannabinoids; Hyperalgesia; Inflammation; Neuropathic pain; Pain

Indexed keywords

2 AMINO 5 PHOSPHONOVALERIC ACID; 2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; AJULEMIC ACID; ANANDAMIDE; BAY 387271; BAY 387281; CANNABIDIOL; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOL; DEXANABINOL; DIZOCILPINE; DRONABINOL; HU 320; INDOLE DERIVATIVE; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PALMIDROL; RIMONABANT; UNCLASSIFIED DRUG;

ALLODYNIA; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; BRAIN PROTECTION; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG STRUCTURE; HEAD INJURY; HUMAN; HYPERALGESIA; INFLAMMATION; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; PAIN; PERIAQUEDUCTAL GRAY MATTER; PRIORITY JOURNAL; REVIEW; TISSUE INJURY;

ANIMALS; CANNABINOIDS; HUMANS; INFLAMMATION; PAIN; RECEPTORS, CANNABINOID;

EID: 3242673487     PISSN: 09254692     EISSN: None     Source Type: Journal    
DOI: 10.1163/1568560041352275     Document Type: Review

References (73)

1. Ahluwalia, J., Urban, L., Bevan, S., et al. (2003). Anandamide regulates neuropeptide release from capsaicin-sensitive primary sensory neurons by activating both the cannabinoid 1 receptor and the vanilloid receptor 1 in vitro, Eur. J. Neurosci. 17, 2611-2618.
2. Arevalo-Martin, A., Vela, J.M., Molina-Holgado, E., et al. (2003). Therapeutic action of cannabinoids in a murine model of multiple sclerosis, J. Neurosci. 23, 2511-2516.
3. Ashton, C. H. (2001). Pharmacology and effects of cannabis: a brief review, Br. J. Psychiatr. 178, 101-106.
4. Baker, D., Pryce, G., Giovannoni, G., et al. (2003). The therapeutic potential of cannabis, Lancet Neurol. 2, 291-298.
5. Bidinger, B., Torres, R., Rossetti, R. G., et al. (2003). Ajulemic acid, a nonpsychoactive cannabinoid acid, induces apoptosis in human T lymphocytes, Clin. Immunol. 108, 95-102.
6. Bridges, D., Ahmad, K. and Rice, A. S. (2001). The synthetic cannabinoid WIN 55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain, Br. J. Pharmacol. 133, 586-594.
7. Bridges, D., Thompson, S. W. N. and Rice, A. S. C. (2001). Mechanisms of neuropathic pain, Br. J. Anaesth. 87, 12-26.
8. Brown, D. T. (Ed.) (1998). Cannabis. The genus Cannabis. Harwood, London.
9. Brown, M., Smyth, G., Rathbone, C., et al. (2003). News in brief, Drug Discov. Today 8, 870-872.
10. Burstein, S. H. (2000). Ajulemic acid (CT3): a potent analog of the acid metabolites of THC, Curr. Pharm. Des. 6, 1339-1345.
11. Cichewicz, D. L. (2004). Synergistic interactions between cannabinoid and opioid analgesics, Life Sci. 74, 1317-1324.
12. Costa, B., Colleoni, M., Conti, S., et al. (2004). Repeated treatment with the synthetic cannabinoid WIN 55,212-2 reduces both hyperalgesia and production of pronociceptive mediators in a rat model of neuropathic pain, Br. J. Pharmacol. 141, 4-8.
13. Costigan, M. and Woolf, C. J. (2000). Pain: molecular mechanisms, J. Pain 1, 35-44.
14. Croxford, J. L. and Miller, S. D. (2003). Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN 55,212, J. Clin. Invest. 111, 1231-1240.
15. Dajani, E. Z., Larsen, K. R., Taylor, J., et al. (1999). 1′,1′-Dimethylheptyl-delta-8 tetrahydrocannabinol-11-oic acid: a novel, orally effective cannabinoid with analgesic and anti-inflammatory properties, J. Pharmacol. Exp. Ther. 291, 31-38.
16. Darlington, C. L. (2003). Dexanabinol: a novel cannabinoid with neuroprotective properties, Drugs 6, 976-979.
17. Devane, W. A., Dysarz, F. A., Johnson, M. R., et al. (1988). Determination and characterisation of a cannabinoid receptor in rat brain, Mol. Pharmacol. 34, 605-613.
18. De Petrocellis, L., Melck, D., Bisogno, T., et al. (2000). Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders, Chem. Phys. Lipids 108, 191-209.
19. Dogrul, A., Gul, H., Akar, A., et al. (2003). Topical cannabinoid antinociception: synergy with spinal sites, Pain 105, 11-16.
20. Ellington, H. C., Cotter, M. A., Cameron, N. E., et al. (2002). The effect of cannabinoids on capsaicin-evoked calcitonin gene-related peptide (CGRP) release from the isolated paw skin of diabetic and non-diabetic rats, Neuropharmacology 42, 966-975.
21. Facchinetti, F., Del Giudice, E., Furegato, S., et al. (2003). Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide, Glia 41, 161-168.
22. Farquhar-Smith, W. P., Egertova, M., Bradbury, E. J., et al. (2000). Cannabinoid CB(1) receptor expression in rat spinal cord, Mol. Cell Neurosci. 15, 510-521.
23. Goutopoulos, A. and Makriyannis, A. (2002). From cannabis to cannabinergics: new therapeutic opportunities, Pharmacol. Ther. 95, 103-117.
24. Grotenhermen, F. (2003). Pharmacokinetics and pharmacodynamics of cannabinoids, Clin. Pharmacokinet. 42, 327-360.
25. Guzman, M., Sanchez, C. and Galve-Roperh, I. (2001). Control of cell survival/death decision by cannabinoids, J. Mol. Med. 78, 613-625.
26. Hall, W. and Solowij, N. (1998). Adverse effects of cannabis, Lancet 352, 1611-1616.
27. Hamann, W. and di Vadi, P. P. (1999). Analgesic effect of the cannabinoid analogue nabilone is not mediated by opioid receptors, Lancet 353, 560.
28. Hohmann, A. G., Martin, W. J., Tsou, K., et al. (1995). Inhibition of noxious stimulus-evoked activity of spinal cord dorsal horn neurons by the cannabinoid WIN 55,212-2, Life Sci. 56, 2111-2118.
29. Hohmann, A. G., Tsou, K. and Walker, J. M. (1998). Cannabinoid modulation of wide dynamic range neurons in the lumbar dorsal horn of the rat by spinally administered WIN-55,212-2, Neurosci. Lett. 257, 119-122.
30. Hohmann, A. G., Briley, E. M. and Herkenham, M. (1999). Pre- and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord, Brain Res. 822, 17-25.
31. Holden, J. E. and Pizzi, J. A. (2003). The challenge of chronic pain, Adv. Drug Deliv. Rev. 55, 935-948.
32. Howlett, A. C. (2002). The cannabinoid receptors, Prostaglandins Other Lipid Mediat. 68-69, 619-631.
33. Howlett, A. C., Barth, F., Bonner, T. I., et al. (2002). International Union of Pharmacology. XXVII. Classification of cannabinoid receptors, Pharmacol. Rev. 54, 161-202.
34. Jan, T. R., Farraj, A. K., Harkema, J. R., et al. (2003). Attenuation of the ovalbumin-induced allergic airway response by cannabinoid treatment in A/J mice, Toxicol. Appl. Pharmacol. 188, 24-35.
35. Janeway, C. A., Travers, P., Walport, M., et al. (1999). Immunobiology: The Immune System in Health and Disease. Elsevier Science, New York, NY.
36. Johns, A. (2001). Psychiatric effects of cannabis, Br. J. Psychiatr. 178, 116-122.
37. Joy, J. E., Watson, S. J. and Benson, J. A. (Eds) (1999). Marijuana and Medicine: Assessing the Science Base. National Academy of Sciences, Washington, DC.
38. Karst, M., Salim, K., Burstein, S., et al. (2003). Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial, J. Am. Med. Ass. 290, 1757-1762.
39. Kehl, L. J., Hamamoto, D. T., Wacnik, P. W., et al. (2003). A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain, Pain 103, 175-186.
40. Kidd, B. L. and Urban L. A. (2001). Mechanisms of inflammatory pain, Br. J. Anaesth. 87, 3-11.
41. Kumar, R. N., Chambers, W. A. and Pertwee, R. G. (2001). Pharmacological actions and therapeutic uses of cannabis and cannabinoids, Anaesthesia 56, 1059-1068.
42. Lim, G., Sung, B., Ji, R.-R., et al. (2003). Up regulation of spinal cannabinoid-1-receptors following nerve injury enhances the effects of win-55,212-2 on neuropathic pain behaviours in rats, Pain 105, 275-283.
43. Malan Jr., T. P., Ibrahim, M. M., Lai, J., et al. (2003). CB2 cannabinoid receptor agonists: pain relief without psychoactive effects?, Curr. Opin. Pharmacol. 3, 62-67.
44. Malfait, A. M., Gallily, R., Sumariwalla, P. F., et al. (2000). The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis, Proc. Natl. Acad. Sci. USA 97, 9561-9566.
45. Matsuda, L. A., Lolait, S. J., Brownstein, M. J., et al. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA, Nature 346, 561-564.
46. Mechoulam, R., Panikashvili, D. and Shohami, E. (2002). Cannabinoids and brain injury: therapeutic implications, Trends Mol. Med. 8, 58-61.
47. Mauler, F., Hinz, V., Augstein, K. H., et al. (2003). Neuroprotective and brain edema-reducing efficacy of the novel cannabinoid receptor agonist BAY 38-7271, Brain Res. 989, 99-111.
48. McCane, K. L. and Huether, S. E. (2002). Pathophysiology: The Biologic Basis for Disease in Adults and Children, 4th edn. Mosby, London.
49. Mechoulam, R., Spatz, M. and Shohami, E. (2002). Endocannabinoids and neuroprotection, Sci. STKE 129, RE5.
50. Meng, I. D., Manning, B. H., Martin, W. J., et al. (1998). An analgesia circuit activated by cannabinoids, Nature 397, 381-383.
51. Merskey, H. and Bogduk, N. (Eds) (1994). Classification of Chronic Pain, 2nd edn. Task force on taxonomy. IASP Press, Seattle, WA.
52. Millns, P. J., Chapman, V. and Kendall, D. A. (2001). Cannabinoid inhibition of the capsaicin-induced calcium response in rat dorsal root ganglion neurones, Br. J. Pharmacol. 132, 969-971.
53. Munro, S., Thomas, K. L. and Abu-Shaar, M. (1993). Molecular characterization of a peripheral receptor for cannabinoids, Nature 365, 61-65.
54. Panikashvili, D., Simeonidou, C., Ben-Shabat, S., et al. (2001). An endogenous cannabinoid (2-AG) is neuroprotective after brain injury, Nature 413, 527-531.
55. Pop, E. (2000). Dexanabinol Pharmos, Curr. Opin. Invest. Drugs 1, 494-503.
56. Porter, A. C. and Felder, C. C. (2001). The endocannabinoid nervous system: unique opportunities for therapeutic intervention, Pharmacol. Ther. 90, 45-60.
57. Richardson, J. D. and Vasko, M. R. (2002). Cellular mechanisms of neurogenic inflammation, J. Pharmacol. Exp. Ther. 302, 839-845.
58. Richardson, J. D., Aanonsen, L. and Hargreaves, K. M. (1998). Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia, J. Neurosci. 18, 451-457.
59. Rice, A. S. C., Farquhar-Smith, W. P. and Nagy, I. (2002). Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy, Prostaglandins Leukotrienes Essent. Fatty Acids 66, 243-256.
60. Ross, R. A., Coutts, A. A., McFarlane, S. M., et al. (2001). Actions of cannabinoid receptor ligands on rat cultured sensory neurones: implications for antinociception, Neuropharmacology 40, 221-232.
61. Saladin, K. S. and Porth, C. M. (1998). Anatomy and Physiology: The Unity of Form and Function. McGraw-Hill, New York, NY.
62. Schaible, H. B., Ebersberger, A. and von Banchet, G. S. (2002). Mechanisms of pain in arthritis, Ann. N.Y. Acad. Sci. 966, 343-354.
63. Shohami, E., Novikov, M. and Mechoulam, R. (1993). A nonpsychotropic cannabinoid, HU-211, has cerebroprotective effects after closed head injury in the rat, J. Neurotrauma 10, 109-119.
64. Shohami, E., Gallilly, R., Mechoulam, R., et al. (1997). Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant, J. Neuroimmunol. 72, 169-177.
65. Straus, S. E. (2000). Immunoactive cannabinoids: therapeutic prospects for marijuana constituents, Proc. Natl. Acad. Sci. USA 97, 9363-9364.
66. Stucky, C. L., Gold, M. S. and Zhang, X. (2001). Mechanisms of pain, Proc. Natl. Acad. Sci. USA 98, 11845-11846.
67. Sumariwalla, P. F., Gallily, R., Tchilibon, S., Fride, E., Mechoulam, R. and Feldmann, M. (2004). A novel synthetic, nopsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis, Arthritis Rheum. 50, 985-998.
68. Vaughan, C. W. and Christie, M. J. (2000). An analgesic role for cannabinoids, Med. J. Austr. 173, 270-272.
69. Walker, J. M. and Huang, S. M. (2002). Cannabinoid analgesia, Pharmacol. Ther. 95, 127-135.
70. Winkelstein, B. A. (2004). Mechanisms of central sensitization, neuroimmunology & injury biomechanics in persistent pain: implications for musculoskeletal disorders, J. Electromyogr. Kinesiol. 14, 87-93.
71. Yesilyurt, O., Dogrul, A., Gul, H., et al. (2003). Topical cannabinoid enhances topical morphine antinociception, Pain 105, 303-308.
72. Zalish, M. and Lavie, V. (2003). Dexanabinol (HU-211) has a beneficial effect on axonal sprouting and survival after rat optic nerve crush injury, Vision Res. 43, 237-242.
73. Zurier, R. B., Rossetti, R. G., Burstein S. H., et al. (2003). Suppression of human monocyte interleukin-1beta production by ajulemic acid, a nonpsychoactive cannabinoid, Biochem. Pharmacol. 65, 649-655.